Paul joined Venture Investors in 2006 as a Managing Director. Paul is focused on the firm’s therapeutics practice. Paul worked as a part-time Analyst for Venture Investors from 1989 to 1992 while receiving his MBA and has been a member of the firm’s Investment Advisory Committee since 2001.
Paul serves on the Board of Directors of FluGen, Invenra, and Madison Vaccines. He is a former board member of Aerpio Pharmaceuticals (NASDAQ:ARPO), Akebia Therapeutics (NASDAQ:AKBA), Neurovance (sold to Otsuka), and Tissue Regeneration Systems.
Paul has over 30 years of investing and operating experience in the biotech and pharmaceutical industries. Previously, he served as President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma Solutions), a division that was established when the Venture Investors portfolio company, Gala Design, Inc., under his leadership was acquired. Prior to joining Gala, Paul served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a venture capital backed biotechnology company with a drug discovery platform that successfully completed an IPO during his tenure, and was subsequently acquired by Johnson & Johnson. Earlier in his career, Paul worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals (now Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs, a division of American Home Products, and Director of Operations for Columbia Research Labs, a publicly held company that focuses and women’s health, which became Juniper Pharmaceuticals (now also part of Catalent Pharma Solutions).
In his spare time, Paul enjoys spending time with family (biking, swimming, and generally goofing off), learning more about wine (and hopefully not buying more!), cooking, and still playing softball and golf as time permits.